This study is a randomized, open-label, controlled, multicenter phase III clinical trial, which plans to randomly enroll 370 subjects with advanced metastatic castration-resistant prostate cancer (mCRPC). The efficacy of HRS-4357 versus novel androgen receptor pathway inhibitors (ARPI) in the treatment of PSMA-positive advanced metastatic castration-resistant prostate cancer (mCRPC) will be evaluated based on radiographic progression-free survival (rPFS) assessed by the BIRC.
Be willing to participate in this clinical trial, understand the study procedures, and be able to sign the informed consent form in writing;
Male, aged ≥ 18 years;
ECOG performance status score of 0-1;
Expected survival time of no less than 6 months;
Any radionuclide therapy or hemi-body radiotherapy within 6 months.
Any PSMA-targeted radiopharmaceutical therapy.
Surgery, radiotherapy, or any local therapy within 4 weeks.
Any other investigational drug intervention within 4 weeks.